Laurie D. Stelzer
2015
In 2015, Laurie D. Stelzer earned a total compensation of $3.8M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $125,000 |
|---|---|
| Option Awards | $2,727,090 |
| Salary | $229,115 |
| Stock Awards | $561,825 |
| Other | $200,333 |
| Total | $3,843,363 |
Stelzer received $2.7M in option awards, accounting for 71% of the total pay in 2015.
Stelzer also received $125K in non-equity incentive plan, $229.1K in salary, $561.8K in stock awards and $200.3K in other compensation.
Rankings
In 2015, Laurie D. Stelzer's compensation ranked 2,290th out of 13,638 executives tracked by ExecPay. In other words, Stelzer earned more than 83.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,290 out of 13,638 | 83rd |
Division Manufacturing | 825 out of 5,187 | 84th |
Major group Chemicals And Allied Products | 295 out of 1,857 | 84th |
Industry group Drugs | 234 out of 1,531 | 85th |
Industry Biological Products, Except Diagnostic Substances | 42 out of 260 | 84th |
Source: SEC filing on March 24, 2017.
Stelzer's colleagues
We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2015.